BACKGROUND Chronic hepatitis B (HB) remains a significant global health concern, despite the widespread availability of the HB vaccine. While the standard vaccine demonstrates an impressive serological response rate exceeding 90%, a subset of individuals exhibit suboptimal immunity. This study aims to elucidate the efficacy of the AS04C-adjuvanted HB vaccine in addressing non-responsiveness. METHODS Conducted at the Preventive Medicine Service of the University Albacete Hospital in Spain from 2017 to 2021, this single-center observational study enrolled 195 patients. Among them, 126 (65%) were classified as non-responders following one or two complete standard vaccination courses. RESULTS After the administration of a complete four-dose regimen of the AS04C-adjuvanted vaccine, 73.81% of non-responder patients exhibited antibody titers indicative of robust immunity (anti-HBs >10). CONCLUSIONS These findings underscore the pivotal role of the AS04C-adjuvanted HB vaccine in addressing non-responsiveness, emphasizing its potential as a crucial tool in augmenting immunization strategies for various populations. This includes non-responders to standard vaccination, individuals with chronic kidney disease, those requiring seroprotection due to factors like immunosuppression or occupational hazards, as well as patients for whom conventional revaccination strategies have proven futile. Additional research is needed to expand on the promising results obtained through our protocol.

中文翻译：

---

在被归类为无反应者的患者中使用 AS04C 佐剂乙型肝炎疫苗。

背景技术 尽管 HB 疫苗已广泛使用，但慢性乙型肝炎 (HB) 仍然是一个重大的全球健康问题。虽然标准疫苗表现出超过 90% 的令人印象深刻的血清学反应率，但仍有一部分个体表现出次优的免疫力。本研究旨在阐明 AS04C 佐剂 HB 疫苗在解决无反应方面的功效。方法 这项单中心观察性研究于 2017 年至 2021 年在西班牙阿尔巴塞特大学医院预防医学部门进行，纳入了 195 名患者。其中，126 人（65%）在完成一到两个标准疫苗接种课程后被归类为无反应者。结果在施用完整的四剂AS04C佐剂疫苗方案后，73.81%的无应答患者表现出表明强大免疫力的抗体滴度（抗-HBs>10）。结论 这些发现强调了 AS04C 佐剂 HB 疫苗在解决无反应方面的关键作用，强调其作为增强不同人群免疫策略的关键工具的潜力。这包括对标准疫苗接种无反应的人、患有慢性肾病的人、由于免疫抑制或职业危害等因素而需要血清保护的人，以及传统重新接种策略已被证明无效的患者。需要进行更多的研究来扩展通过我们的协议获得的有希望的结果。